123 related articles for article (PubMed ID: 19115211)
1. Frequent concomitant epigenetic silencing of the stress-responsive tumor suppressor gene CADM1, and its interacting partner DAL-1 in nasal NK/T-cell lymphoma.
Fu L; Gao Z; Zhang X; Tsang YH; Goh HK; Geng H; Shimizu N; Tsuchiyama J; Srivastava G; Tao Q
Int J Cancer; 2009 Apr; 124(7):1572-8. PubMed ID: 19115211
[TBL] [Abstract][Full Text] [Related]
2. Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas.
Heller G; Fong KM; Girard L; Seidl S; End-Pfützenreuter A; Lang G; Gazdar AF; Minna JD; Zielinski CC; Zöchbauer-Müller S
Oncogene; 2006 Feb; 25(6):959-68. PubMed ID: 16205641
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer.
Heller G; Geradts J; Ziegler B; Newsham I; Filipits M; Markis-Ritzinger EM; Kandioler D; Berger W; Stiglbauer W; Depisch D; Pirker R; Zielinski CC; Zöchbauer-Müller S
Breast Cancer Res Treat; 2007 Jul; 103(3):283-91. PubMed ID: 17260099
[TBL] [Abstract][Full Text] [Related]
4. Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer.
Takahashi Y; Iwai M; Kawai T; Arakawa A; Ito T; Sakurai-Yageta M; Ito A; Goto A; Saito M; Kasumi F; Murakami Y
Breast Cancer; 2012 Jul; 19(3):242-52. PubMed ID: 21526423
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma.
Hui AB; Lo KW; Kwong J; Lam EC; Chan SY; Chow LS; Chan AS; Teo PM; Huang DP
Mol Carcinog; 2003 Dec; 38(4):170-8. PubMed ID: 14639656
[TBL] [Abstract][Full Text] [Related]
6. CADM1/TSLC1 inactivation by promoter hypermethylation is a frequent event in colorectal carcinogenesis and correlates with late stages of the disease.
Chen K; Wang G; Peng L; Liu S; Fu X; Zhou Y; Yu H; Li A; Li J; Zhang S; Bai Y; Zhang Y
Int J Cancer; 2011 Jan; 128(2):266-73. PubMed ID: 20340131
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic silencing of a proapoptotic cell adhesion molecule, the immunoglobulin superfamily member IGSF4, by promoter CpG methylation protects Hodgkin lymphoma cells from apoptosis.
Murray PG; Fan Y; Davies G; Ying J; Geng H; Ng KM; Li H; Gao Z; Wei W; Bose S; Anderton J; Kapatai G; Reynolds G; Ito A; Marafioti T; Woodman CB; Ambinder R; Tao Q
Am J Pathol; 2010 Sep; 177(3):1480-90. PubMed ID: 20709797
[TBL] [Abstract][Full Text] [Related]
8. Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC.
Overmeer RM; Henken FE; Snijders PJ; Claassen-Kramer D; Berkhof J; Helmerhorst TJ; Heideman DA; Wilting SM; Murakami Y; Ito A; Meijer CJ; Steenbergen RD
J Pathol; 2008 Aug; 215(4):388-97. PubMed ID: 18498117
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific methylation of the 8p22 tumor suppressor gene DLC1 is an epigenetic biomarker for Hodgkin, nasal NK/T-cell and other types of lymphomas.
Ying J; Li H; Murray P; Gao Z; Chen YW; Wang Y; Lee KY; Chan AT; Ambinder RF; Srivastava G; Tao Q
Epigenetics; 2007; 2(1):15-21. PubMed ID: 17965626
[TBL] [Abstract][Full Text] [Related]
10. Expression of TSLC1, a candidate tumor suppressor gene mapped to chromosome 11q23, is downregulated in unfavorable neuroblastoma without promoter hypermethylation.
Ando K; Ohira M; Ozaki T; Nakagawa A; Akazawa K; Suenaga Y; Nakamura Y; Koda T; Kamijo T; Murakami Y; Nakagawara A
Int J Cancer; 2008 Nov; 123(9):2087-94. PubMed ID: 18726896
[TBL] [Abstract][Full Text] [Related]
11. Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma.
Nowacki S; Skowron M; Oberthuer A; Fagin A; Voth H; Brors B; Westermann F; Eggert A; Hero B; Berthold F; Fischer M
Oncogene; 2008 May; 27(23):3329-38. PubMed ID: 18084322
[TBL] [Abstract][Full Text] [Related]
12. The stress-responsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors.
Ying J; Srivastava G; Hsieh WS; Gao Z; Murray P; Liao SK; Ambinder R; Tao Q
Clin Cancer Res; 2005 Sep; 11(18):6442-9. PubMed ID: 16166418
[TBL] [Abstract][Full Text] [Related]
13. Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies.
Ying J; Gao Z; Li H; Srivastava G; Murray PG; Goh HK; Lim CY; Wang Y; Marafioti T; Mason DY; Ambinder RF; Chan AT; Tao Q
Br J Haematol; 2007 Mar; 136(6):829-32. PubMed ID: 17341268
[TBL] [Abstract][Full Text] [Related]
14. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma.
Murray PG; Qiu GH; Fu L; Waites ER; Srivastava G; Heys D; Agathanggelou A; Latif F; Grundy RG; Mann JR; Starczynski J; Crocker J; Parkes SE; Ambinder RF; Young LS; Tao Q
Oncogene; 2004 Feb; 23(6):1326-31. PubMed ID: 14961078
[TBL] [Abstract][Full Text] [Related]
15. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma.
Qiu GH; Tan LK; Loh KS; Lim CY; Srivastava G; Tsai ST; Tsao SW; Tao Q
Oncogene; 2004 Jun; 23(27):4793-806. PubMed ID: 15122337
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas.
Wang Z; Li L; Su X; Gao Z; Srivastava G; Murray PG; Ambinder R; Tao Q
J Transl Med; 2012 Oct; 10():209. PubMed ID: 23050586
[TBL] [Abstract][Full Text] [Related]
17. IGSF4 promoter methylation and expression silencing in human cervical cancer.
Li J; Zhang Z; Bidder M; Funk MC; Nguyen L; Goodfellow PJ; Rader JS
Gynecol Oncol; 2005 Jan; 96(1):150-8. PubMed ID: 15589594
[TBL] [Abstract][Full Text] [Related]
18. Tumor suppressor CADM1 is involved in epithelial cell structure.
Sakurai-Yageta M; Masuda M; Tsuboi Y; Ito A; Murakami Y
Biochem Biophys Res Commun; 2009 Dec; 390(3):977-82. PubMed ID: 19854157
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of PRDM1/Blimp-1 promoter in extranodal NK/T-cell lymphoma, nasal type: an evidence of predominant role in its downregulation.
Zhang Z; Liang L; Li D; Nong L; Liu J; Qu L; Zheng Y; Zhang B; Li T
Hematol Oncol; 2017 Dec; 35(4):645-654. PubMed ID: 27704586
[TBL] [Abstract][Full Text] [Related]
20. Aberrant methylation of the CADM1 promoter is associated with poor prognosis in hepatocellular carcinoma treated with liver transplantation.
Zhang W; Zhou L; Ding SM; Xie HY; Xu X; Wu J; Chen QX; Zhang F; Wei BJ; Eldin AT; Zheng SS
Oncol Rep; 2011 Apr; 25(4):1053-62. PubMed ID: 21271221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
